Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Madrigal Pharmaceuticals

Madrigal Pharmaceuticals Clears Technical Benchmark, Hitting 90-Plus RS Rating

Madrigal Pharmaceuticals sees its Relative Strength Rating move into the elite 90-plus level.

Investors Business Daily

Stocks With Rising Relative Price Strength: Madrigal Pharmaceuticals

A Relative Strength Rating upgrade for Madrigal Pharmaceuticals shows improving technical performance.

Investors Business Daily

Madrigal Pharmaceuticals Shows Market Leadership With Jump To 91 RS Rating

Madrigal Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Stocks To Watch: Madrigal Pharmaceuticals Sees RS Rating Rise To 91

Madrigal Pharmaceuticals sees its Relative Strength Rating enter the elite 90-plus level.

Investors Business Daily

Novo Nordisk: A New Boost for GLP-1 Sales on the Horizon

Novo Nordisk A/S is moving closer to adding more sales for its blockbuster GLP-1 drug semaglutide to treat a chronic liver disease.

MarketBeat

Top 3 Health Care Stocks That May Dip This Month

As of Nov. 25, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Benzinga

Madrigal Pharmaceuticals Clears Key Benchmark, Hitting 90-Plus RS Rating

A Relative Strength Rating upgrade for Madrigal Pharmaceuticals shows improving technical performance.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Madrigal Pharmaceuticals Shows Market Leadership With Jump To 92 RS Rating

Madrigal Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.

Investors Business Daily

Madrigal Pharmaceuticals Stock Earns RS Rating Upgrade

Madrigal Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.

Investors Business Daily

Madrigal Pharmaceuticals Stock Hits 80-Plus Relative Strength Rating Benchmark

Madrigal Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 63 to 83.

Investors Business Daily

Madrigal Pharmaceuticals Stock Shows Rising Relative Strength

A Relative Strength Rating upgrade for Madrigal Pharmaceuticals shows improving technical performance.

Investors Business Daily

Madrigal Pharmaceuticals Stock Clears Benchmark, Hits 80+ RS Rating

Madrigal Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 86.

Investors Business Daily

Johnson & Johnson (JNJ) vs. Madrigal Pharmaceuticals (MDGL): Which Pharma Stock Is a Worthier October Investment?

With an aging population worldwide, the growing prevalence of chronic diseases, new drug discoveries and rapid digital advancements, the outlook for the pharmaceutical sector remains optimistic. Pharma stocks Johnson & Johnson (JNJ) and Madrigal Pharmaceuticals (MDGL) will likely benefit from the industry’s bright prospects. But which of these stocks is…

StockNews.com

Madrigal Pharmaceuticals Surges As Its NASH Treatment Toes The Long-Awaited Finish Line

Madrigal said Wednesday it could win FDA approval for its nonalcoholic steatohepatitis treatment in March, and MDGL stock jumped.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Why Top 1% Biotech Madrigal Pharmaceuticals Just Surged Closer To A Breakout

Madrigal snagged a breakthrough therapy designation for its liver disease treatment on Tuesday and MDGL stock surged closer to a buy point.

Benzinga

How To Attend Madrigal Pharmaceuticals Q1 2022 Earnings Conference Call

Madrigal Pharmaceuticals (NASDAQ:MDGL) will host a conference call at 08:00 AM ET on May 9, 2022, to discuss Q1 2022 earnings results.

People

Mangeet Kaur BounsMangeet

595 stories

Thomas Smith

44 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Madrigal Pharmaceuticals

Read news from The Economist, FT, and more,
with one subscription

Topics

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.